In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Selling to the Franchise Market

Executive Summary

From its inception, Triangle pursued a strategy of building a broad portfolio of antiviral drugs through in-licensing, with the goal of bringing drug candidates through later stage clinical trials and then partnering the entire deal package with a single partner. Triangle's June 1999 deal with Abbott was just such a deal. The agreement, which involves 2 Abbott drugs and 4 Triangle compounds may provide Abbott with franchises in HIV & HBV. Triangle meanwhile stands to reap up to $335 million. For the industry as a whole, the deal suggests that there may be increased opportunities for biotechs to make lucrative deals for niche products, particularly when they can offer a portfolio that will help its partner build a franchise.

You may also be interested in...

Gilead Gets Triangle, and a Product It Can Leverage

Gilead's acquisition of Triangle is a clear example of a strong company buying a weak company's assets. Triangle lost the market's confidence, and its partner Abbott, through prolonged clinical difficulties that sapped its cash. Gilead bought the company primarily to get an AIDS drug, Coviricil, that will likely soon win US marketing approval. Gilead aims to co-formulate that compound with its own AIDS drug Viread, to create the first one-pill, once-daily combination therapy for AIDS. Gilead has earned a reputation for finding under-valued assets and turning them into value drivers for itself. Looks like it's at it again.

Stockwatch: Reading The Tea Leaves For Pharma Q1 Earnings

Contrasting first-quarter preannouncements from a DNA sequencing company and a molecular diagnostics company may, with other seasonal pressures, imply a comparatively weak first quarter for therapeutic drug companies.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts